Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma.
Journal
Revista espanola de enfermedades digestivas
ISSN: 1130-0108
Titre abrégé: Rev Esp Enferm Dig
Pays: Spain
ID NLM: 9007566
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
pubmed:
23
3
2022
medline:
20
4
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.
Identifiants
pubmed: 35315679
doi: 10.17235/reed.2022.8775/2022
doi:
Substances chimiques
Yttrium Radioisotopes
0
Yttrium-90
1K8M7UR6O1
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM